A2A-Selective Adenosine Receptor Antagonists: Development of Water-Soluble Prodrugs and a New Tritiated Radioligand

Drug Development Research

Volumn 45, Issue 3-4, 1998, Pages 190-197

  Müller, Christa E ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

A2a adenosine receptor antagonists; MSX 3; Parkinson's disease; Phosphates; Prodrugs; Radioligand; 3h msx 2

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; MSX 2; MSX 3; PRODRUG; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CATALEPSY; CONFERENCE PAPER; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; INTRACEREBRAL DRUG ADMINISTRATION; NONHUMAN; RAT;

EID: 0032469488     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2299(199811/12)45:3/4<190::aid-ddr16>3.0.co;2-a     Document Type: Article

References (28)

1. Baraldi PG, Cacciari B, Spalluto G, Borioni A, Viziano M, Dionisotti S, Ongini E. 1995. Current developments of A£A adenosine receptor antagonists. Curr Med Chem 2:707-722.
2. Burnstock G, Wood JN. 1996. Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 6:526-532.
3. Daly JW, Padgett WL, Shamin MT. 1986. Analogues of caffeine and theophylline: effects of stmctural alterations on affinity at adenosine receptors. J Med Chem 29:1305-1308.
4. Guieu R, Devaux C, Henry H, Bechis G, Pouget J, Mallet D, Sampieri F, Juin M, Gola R, Rochat H. 1998. Adenosine and migraine. Can J Neurol Sei 25:55-58.
5. Hauber W, Nagel J, Sauer R, Müller CE. 1998. Motor effects induced by a blockade of adenosine A\ receptors in the caudate-putamen. Neuroreport 9:1803-1806.
6. Higuchi T. 19S7. Prodrug and drug deliver)': an overview. In: Roche EB, editor. Bioreversible carriers in drug design: theory and application. New York: Pergamon Press, p 1-94.
7. Jacobson KA, Suzuki E 1996. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. Dnig Dev Res 39:289-300.
8. KandaT, Shiozaki S, Shimada J, Suzuki F, Nakamura J. 1994. KF17837: a novel selective adenosine A2.\ receptor antagonist with anticataleptic activity. Eur J Pharmacol 256:263-268.
9. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Käse H, Kuwana Y, Jenner P 1998. Adenosine AJA antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513.
10. Klotz KN, Hessling J, Hegler-J, Owman C, Kuli B, Fredholm BB, Lohse MJ. 1998. Comparative pharmacology of human adenosine receptor subtypes: characterization of stably transfecled receptors in CIIO cells. Naunyn Schmiederberg Arch Pharmacol 357:1-9.
11. Ledent C, Vaugeois J-M, Schiffmann SN, Pedrazzini T, Yacoubi ME, Vanderhaeghen J-J, Costentin J, Healli JK, Vassart G, Parmentier M. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A£A receptor. Nature 388:674-678.
12. Leenders RGG, Scheeren HW. 1995. Synthesis and evaluation of novel daunoinycin-phosphale-sulfate-ß-glucuronide and -ß-glucoside prodrugs for application in ADEPT. Bioorg Med Chem Lett 5:2975-2980.
13. Matuszczak B, Pekala E, Müller CE. 1998. 1-Substituted 4[chloropyrazolyl]-[l,2,4]triazolo[4,3-fl]quinoxalines: synthesis and structure-activity relationships of a new class of benzodiazepine and adenosine receptor ligands. Arch Pharm Med Chem 331:163-169.
14. Monopoli A, Lozza G, Mattavelli'A, Forlani A, Ongini E. 1998. Neuroprotective effects of the A£A adenosine receptor antagonist SCH58261 in the permanent cerebral ischemia model in the rat. Dnig Dev Res (abstract) 43:71.
15. Müller CE, Sandoval-Ramîrez J. 1995. A new versatile synthesis of xanthines with variable substituents in the 1- ,3- ,7- and 8-positions. Synthesis 1295-1299.
16. Müller CE, Stein B. 1996. Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr Pharm Design 2:501-530.
17. Müller CE, Geis U, Hipp J, Schobert U, Frobenius W, Pawlowski M, Suzuki F, Sandoval-Raimrez J. 1997a. Synthesis and structure-activity relationships of 3,7-dimethyI-l-propargylxantine derivatives, A2A-selective adenosine receptor antagonists. J Med Chem 40:43964405.
18. Müller CE, Sauer R, Geis U, Frobenius \V, Talik P, Pawlowski M. 1997b. Aza-analogs of 8-styrylxanthines as Ai\-adenosine receptor antagonists. Arch Pharm Med Chem 330:181-189.
19. Müller CE, Sandoval-Ramîrez J, Schobert U, Geis U, Frobenius W, Klotz K-N. 1998.8-(Sulfostyryl)xanthines: water-soluble Ai\-selective adenosine receptor antagonists. Bioorg Med Chem 6:707-719.
20. Ongini E, Fredholm B. 1996. Pharmacology of adenosine AJA receptors. Trends Pharmacol Sei 17:364-372.
21. Ongini E, Dionisotti S, Morelli M, Ferré S, Svenningsson P, Fuxe K, Fredholm BB. 1996. Neurophannacology of the adenosine Aj.\ receptors. Drug Dev Res 39:450-460.
22. Perich JW, Johns RB. 19S8. Di-fcri-butyl N,N-diethy]phosphoramidite. A new phosphitylating agent for the efficient phosphorylation of alcohols. Synthesis 142-144.
23. Phillis JW. 1995. The effects of selective Al and A2a adenosine receptor antagonists on cerebral ischémie injury in the gerbil. Brain Res 705:79-84.
24. Richardson PJ, Käse H, Jenner PG. 1997. Adenosine AJA receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sei 18:338-344.
25. Sawynok J. 1998. Adenosine receptor activation and nociception. Eur JPhannacol 317:1-11.
26. Shimada J, Koike N, Nonaka H, Shiozaki S, Yanagawa K, Kanda T Kobayashi II, Ichimura M, Nakamura J, Kase H, Suzuki E 1997. Adenosine AJA antagonists with potent anti-cataleptic activity. Bioorg Med Chem Lett 7:2349-2352.
27. Snyder SH. 1997. Knockouts anîious for new therapy. Nature 388:624.
28. Von Lubitz DKJE, Lin RCS, Jacobson KA. 1995. Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2a receptor agonist and antagonist. Eur J Pharmacol 287:295-302.